04. September 2018
Diabetes mellitus is a highly prevalent metabolic and chronic disease affecting millions of people in the world. The most common route of insulintherapy is the subcutaneous injection due to its low bioavailability and enzymatic degradation. The search for effective and high patient compliance insulin delivery systems has been a major challenge over many decades. The polysaccharide-based nanoparticles as delivery vehicles for insulin oral administration have recently attracted substantial...
28. September 2017
Purpose of Review Faster aspart is a new formulation of insulin aspart (IAsp) produced by adding the excipients niacinamide and L-arginine. As this new, “ultra-rapid insulin” is available in the EU-market and Canada, the pharmacokinetic and pharmacodynamics data is summarized. Recent Findings Faster aspart shows an earlier onset of appearance of insulin in the bloodstream after subcutaneous administration and an earlier onset of glucose-lowering action and a higher glycemic effect within...
06. June 2016
Introduction: Insulin allergy to human insulin preparations during the treatment of diabetes is suggested to occur at rates ranging from <1.0% to 2.4%. These reactions vary from mild localized reactions, which resolve with repeated exposure, to life-threatening anaphylaxis and death. The management of persistent insulin allergy in type 1 diabetes mellitus is particularly complicated because ongoing treatment with insulin is essential. Case presentation: We present the case of a 12-year-old...
24. May 2016
Patients tend to prevent hypoglycemia by excessive saccharide intake leading to poorer glycemic control with potentially fatal consequences. This problem could be resolved by means of pellets with glucose release delayed by 120–360 min as a compensation of the antidiabetic drug peak effect. No glucose is released before; hence there is no risk of hyperglycemia and secondary complications. The pellets contain glucose in combination with an osmotically active ingredient and are coated with an...
18. March 2016
Abstract: The objective of this study was to design and evaluate Sitagliptin Phosphate immediate release (IR) 50 mg tablet using Response Surface Methodology for the managemant of Type-II diabetes mellitus. Response surface methodology (RSM) computations for this optimization study were performed employing Minitab 16. Different formulations of immediate release were prepared by applying 2 factor 2 level Central Composite Design (CCD) using Minitab 16 which gave 13 formulation for each layer....
27. July 2015
Context: We previously designed, developed and characterized a novel microencapsulated formulation as a platform for the targeted delivery of Probucol (PB) in an animal model of Type 2 Diabetes. Objective: The objective of this study is to optimize this platform by incorporating Chenodeoxycholic acid (CDCA), a bile acid with good permeation-enhancing properties, and examine its effect in vitro. More